WuXi Biologics (Cayman)'s quarterly market cap
increased
from Dec. 2024 ($8,910 Mil) to Jun. 2025 ($12,939 Mil) and
increased
from Jun. 2025 ($12,939 Mil) to Dec. 2025 ($17,444 Mil).
WuXi Biologics (Cayman)'s annual market cap
declined
from Dec. 2023 ($15,795 Mil) to Dec. 2024 ($8,910 Mil) but then
increased
from Dec. 2024 ($8,910 Mil) to Dec. 2025 ($17,444 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. WuXi Biologics (Cayman)'s Enterprise Value for Today is $17,444 Mil.
WuXi Biologics (Cayman) (OTCPK:WXIBF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
WuXi Biologics (Cayman) Market Cap Related Terms
WuXi Biologics (Cayman) Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, WuXi Biologics (Cayman)'s Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi Biologics (Cayman) Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s Market Cap distribution charts can be found below:
* The bar in red indicates where WuXi Biologics (Cayman)'s Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
WuXi Biologics (Cayman)'s Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi Biologics (Cayman) (WXIBF) has a Market Cap of $18,129 Mil as of Jun. 30, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on WuXi Biologics (Cayman) and its competitors. According to the industry distribution chart, WuXi Biologics (Cayman) ranks #17 out of 1428 companies in the Biotechnology industry, placing it in the top 1.2%.
Is WuXi Biologics (Cayman)'s Market Cap too high?
WuXi Biologics (Cayman)'s current Market Cap is $18,129 Mil. The Biotechnology industry median Market Cap is 119.44. WuXi Biologics (Cayman)'s value of $18,129 Mil is 15078% above this industry median. Based on the distribution chart, WuXi Biologics (Cayman) ranks #17 out of 1428 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, WuXi Biologics (Cayman) has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does WuXi Biologics (Cayman)'s Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, WuXi Biologics (Cayman) ranks #17 out of 1428 companies for Market Cap. This places WuXi Biologics (Cayman) in the top 1% of its industry — outperforming the majority of peers. The industry median Market Cap is 119.44. WuXi Biologics (Cayman)'s value of $18,129 Mil is 15078% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.44, based on 1,428 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WuXi Biologics (Cayman)'s current Market Cap of $18,129 Mil is 15078% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on WuXi Biologics (Cayman) and its competitors. For the Biotechnology industry, the median Market Cap is 119.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WuXi Biologics (Cayman)'s current Market Cap is $18,129 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi Biologics (Cayman) stock overvalued right now?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) (WXIBF) is currently considered Modestly Undervalued. The stock's GF Value™ is $4.62, compared to a current price of $4.00 — trading 13.4% below its estimated fair value. The current Market Cap is $18,129 Mil and 15078% above the Biotechnology industry median of 119.44. WuXi Biologics (Cayman)'s overall GF Score™ is 97/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For WuXi Biologics (Cayman) (WXIBF), the current Market Cap is $18,129 Mil as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WuXi Biologics (Cayman) (WXIBF) Overvalued in 2026?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be undervalued.
The current stock price of $4.00 is trading 13.4% below its estimated GF Value™ of $4.62.
GuruFocus considers WuXi Biologics (Cayman) to be Modestly Undervalued.
Key valuation signals for WXIBF:
Market Cap: $18,129 Mil
GF Value™: $4.62 vs. price of $4.00 (13.4% below fair value)
Industry Position: 15078% above the Biotechnology median (#17 of 1428)
No single metric tells the full story. See the WXIBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
97GF Score
Get the complete analysis for WXIBF
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WXIBF has been successfully added to your 
